Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Packaging for amorphous statins and compositions thereof

a technology of amorphous statins and packaging, which is applied in the direction of containers, tray containers, diagnostics, etc., can solve the problems of reducing the therapeutic effect of an active substance, and unnecessarily burdening the body with degradation products, etc., to achieve easy detection, improve stability, and reduce the effect of oxidation

Inactive Publication Date: 2009-03-19
RANBAXY LAB LTD
View PDF6 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes a packaging system for amorphous statins to enhance their stability. This can be achieved by using a vacuum, which provides additional benefits such as requiring less space and being less prone to leakage. The packaging system includes an amorphous statin and a stabilizer such as an oxygen absorber or moisture absorber. The stabilizer can be packaged in a separate bag or in the same bag as the statin. The packaged system can be placed in a rigid container for easy handling. The technical effects of this patent text are improved stability of amorphous statins and a more efficient and reliable packaging system."

Problems solved by technology

However, amorphous forms can be susceptible to oxidation, heat, light, moisture and low pH, as compared to crystalline forms.
Impurities generated upon degradation of active substances can reduce the therapeutic effects of an active substance and unnecessarily burden the body with degradation products.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0078]Atorvastatin drug substance (amorphous) was packaged for long term use or transporting according to various packaging options as described below:[0079]1. Amorphous atorvastatin was packaged in a LDPE bag and flushed with nitrogen gas; the bag was twisted and tied; the bag was put into a double laminated bag along with oxygen absorber and flushed with nitrogen gas; vacuum was applied to the double laminated bag and heat sealed; the sealed double laminated bag was packaged into a triple laminated bag along with molecular sieve and flushed with nitrogen gas; vacuum was applied to the triple laminated bag and heat sealed.[0080]2. Amorphous atorvastatin was packaged in a LDPE bag and flushed with nitrogen gas; the bag was twisted and tied; the bag was put into a double laminated bag along with oxygen absorber and silica gel; vacuum was applied to the double laminated bag and heat sealed; sealed double laminated bag was packaged into a triple laminated bag along with molecular sieve...

example 2

[0084]Atorvastatin tablets according to WO 03 / 068191 were packaged in following packaging options and were subjected to stability studies:[0085]1. Tablets and molecular sieve were packaged in a double laminated bag and vacuum sealed; double laminated bag was packaged into a HDPE bottle containing oxygen absorber,[0086]2. Tablets and molecular sieve were packaged in a triple laminated bag and vacuum sealed; triple laminated bag was packaged into a HDPE bottle containing oxygen absorber,[0087]3. Tablets and molecular sieve were packaged in a double laminated bag and vacuum sealed; vacuum sealed bag was then put in a triple laminated bag containing oxygen absorber; and packaged into a HDPE bottle.

[0088]Example 2, option 2 and 3 were subjected to stability studies at 40° C. and 75% RH, the results are given in the Table 2:

TABLE 2The stability data of Atorvastatin tablets as per Example 2, option 2 and 3at 40° C. and 75% RH.1 month3 monthImpurity typeInitialOption 2Option 3Option 2Option...

example 3

[0089]An exhibit batch was taken for Atorvastatin tablets according to WO 03 / 068191; and were packaged in following packaging options and subjected to stability studies:[0090]1. A total of 30 tablets were packaged in a triple laminated bag and vacuum sealed; triple laminated bag was packaged into a HDPE bottle containing oxygen absorber and the bottle was sealed using heat induction.[0091]2. A total of 90 tablets were packaged in a triple laminated bag and vacuum sealed; triple laminated bag was packaged into a HDPE bottle containing oxygen absorber and the bottle was sealed using heat induction.[0092]3. A total of 90 tablets were packaged in a triple laminated bag and vacuum sealed; triple laminated bag was packaged into a HDPE bottle containing molecular sieve and the bottle was sealed using heat induction.

[0093]Example 3, option 1-3 were subjected to stability studies at 40° C. and 75% RH after 3 months.

TABLE 3The stability data of Atorvastatin tabletsas per Example 3 at 40° C. a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
mean particle size d50aaaaaaaaaa
mean particle size d50aaaaaaaaaa
RHaaaaaaaaaa
Login to View More

Abstract

The present publication relates to a vacuum-sealed pack comprising an amorphous statin or a pharmaceutical composition thereof and at least one stabilizer such as, for example, an oxygen absorber, a moisture absorber or a combination thereof.

Description

FIELD OF THE INVENTION[0001]The present invention relates to a vacuum sealed pack comprising an amorphous statin and at least one stabilizer such as, for example, an oxygen absorber, a moisture absorber or a combination thereof.BACKGROUND OF THE INVENTION[0002]Statins are currently among the most therapeutically effective drugs available for reducing the level of LDL in the blood stream of a patient at risk for cardiovascular disease. Statins are also known to raise HDL cholesterol levels and decrease total triglyceride levels. The mechanism of action of statins has been elucidated in some detail. It is believed that statins disrupt the biosynthesis of cholesterol and other sterols in the liver by competitively inhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase enzyme (“HMG-CoA reductase”). HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, which is the rate determining step in the biosynthesis of cholesterol. Consequently, its inhibition leads to a re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): B65D85/00
CPCA61J1/00A61J1/16A61K31/40A61K9/2018A61K9/2054A61K9/2009
Inventor BAHUGUNA, SUMITMUNSHI, ANINDYAMATHUR, RAJEEV SHANKARAGGARWAL, SWATISINGH, ROMI BARATSATHYANARAYANA, SWARGAMKUMAR, SARIDI MADHAVA
Owner RANBAXY LAB LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com